Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee CME information and select publications

Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, including the following topics: Introduction: Looking Back at Immuno-oncology Therapies (0:00) Metastatic Disease (7:46) Localized Non-Small Cell Lung Cancer (42:16) Small Cell Lung Cancer (59:48) CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Introduction: Antibody-Drug Conjugates in Breast Cancer (0:00) Case: A premenopausal woman in her late 40s with 0.8-cm ER/PR-positive, HER2-negative invasive ductal carcinoma (IDC) with 2 positive nodes and an Oncotype DX® Recurrence Score® (RS) of 9 — Ranju Gupta, MD (13:59) Case: A premenopausal woman in her early 40s with 5-cm ER/PR-positive, HER2-negative Grade I IDC — Nick Leasure, MD (17:43) Case: A woman in her early 70s with ER/PR-positive, HER2-low (IHC 1+) metastatic IDC receiving T-DXd with mixed response — Gigi Chen, MD (38:38) Case: A woman in her late 40s with multicentric triple-negative breast cancer with a gBRCA1 mutation who receives treatment per KEYNOTE-522 and achieves a complete remission with neoadjuvant treatment — Zanetta S Lamar, MD (44:27) Case: A premenopausal woman in her early 50s with bilateral ER/PR-positive, HER2-negative, IDC with PALB2 mutation and multiple, bilateral positive nodes — William R Mitchell, MD (46:44) Case: A woman in her mid 30s who is 18 weeks pregnant and is diagnosed with ER/PR-positive, HER2-negative IDC and an Oncotype DX RS of 17 — Alan B Astrow, MD (50:48) Case: A woman in her late 40s with ER/PR-positive, HER2-negative metastatic breast cancer with NTRK mutation and CNS involvement who receives entrectinib — Rahul Gosain, MD (52:55) Case: A woman in her early 60s with ER/PR-positive, HER2-negative metaplastic breast cancer with an Oncotype DX RS of 51 who has received an adjuvant aromatase inhibitor for 16 years — Rajalaxmi McKenna, MD (56:04) CME information and select publications

Featuring perspectives from Drs Robert L Coleman, Matthew A Powell and Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics: Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability (MSI)-High/Mismatch Repair (MMR)-Deficient Endometrial Cancer — Dr Powell Introduction (0:00) Case: A woman in her early 60s with MSI-high recurrent endometrioid adenocarcinoma of the uterus experiences progression after minimal response to carboplatin/paclitaxel — Lyndsay J Willmott, MD (2:25) Case: A woman in her early 50s with MSI-high metastatic endometrial adenocarcinoma after rapid, highly symptomatic progressive disease on paclitaxel/carboplatin — Kellie E Schneider, MD (8:21) Faculty presentation: Dr Powell (14:35) Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman Case: A woman in her early 60s with a 10-cm right ovarian mass and right pelvic adenopathy; total abdominal hysterectomy with bilateral salpingo-oophorectomy and para-aortic lymph node dissection reveal microsatellite stable (MSS) carcinosarcoma of the endometrium with right ovary and pelvic lymph node involvement (R0); adjuvant paclitaxel/carboplatin administered — Thomas P Morrissey, MD (24:46) Case: A woman in her late 60s with Stage IB, Grade 1 endometrial cancer after hysterectomy/sentinel lymph node biopsy — Dana M Chase, MD (30:11) Faculty presentation: Dr Coleman (35:54) Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin Case: A woman in her early 60s with a family history of breast cancer — Dr Morrissey (46:05) Case: A woman in her mid 70s who underwent hysterectomy, lymphadenectomy, omentectomy and 6 cycles of carboplatin/paclitaxel for a Stage IB MSS serous endometrial cancer; develops metastatic disease to the lungs 11 months later and is started on lenvatinib/pembrolizumab — Dr Chase (51:36) Faculty presentation: Dr Westin (57:09) Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz Case: A woman in her early 70s with HER2-positive serous carcinoma of the uterus receives adjuvant carboplatin/paclitaxel and trastuzumab, now no evidence of disease and receiving maintenance trastuzumab — Dr Willmott (1:07:34) Case: A woman in her early 80s with MSI-high metastatic endometrial cancer who receives talazoparib on the TAPUR clinical trial after experiencing progressive disease on pembrolizumab after 4 cycles — John K Chan, MD (1:13:01) Faculty presentation: Dr Slomovitz (1:18:53) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 2: Myelodysplastic Syndromes — Dr Uma Borate, MD, MS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 1: Acute Myeloid Leukemia — Prof Andrew H Wei CME information and select publications

Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML): Key Papers and Presentations (3:30) Myelodysplastic Syndromes (MDS): Key Papers and Presentations (36:32) CME information and select publications

Featuring perspectives from Dr Jacob Laubach, including the following topics: Evolution of first-line treatment for multiple myeloma (MM) (0:00) Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27) ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35) ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57) ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05) ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33) Bispecific antibody therapy administration and patient education (52:41) ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17) CME information and select publications

Featuring perspectives from Dr Matthew Milowsky and Prof Thomas Powles, including the following topics: • Introduction (0:00) • Renal Cell Carcinoma (3:23) • Urothelial Bladder Cancer (35:05) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 2: Urothelial Bladder Cancer — Matthew Milowsky, MD CME information and select publications